ACADIA PHARMACEUTICALS INC. Prepaid Expense, Current
ACADIA PHARMACEUTICALS INC. (ACAD) had Prepaid Expense, Current of $64.60 million as of 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Balance Sheet › Assets › Assets, Current › Prepaid Expense, Current
us-gaap:PrepaidExpenseCurrent · last filed 2026-05-07
- 2026-03-31: Prepaid Expense, Current $64.60M.
- 2025-12-31: Prepaid Expense, Current $59.53M.
- 2025-09-30: Prepaid Expense, Current $60.87M.
- 2025-06-30: Prepaid Expense, Current $52.75M.
| Period end | Prepaid Expense, Current |
|---|---|
| 2026-03-31 | $64.60M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $59.53M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $60.87M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $52.75M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $52.70M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $55.68M 10-K · filed 2026-02-26 |
| 2024-09-30 | $51.55M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $46.06M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $42.76M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $39.09M 10-K · filed 2025-02-27 |
| 2023-09-30 | $37.95M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $23.89M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $23.63M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $21.40M 10-K · filed 2024-02-28 |
| 2022-09-30 | $22.99M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $20.95M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $25.75M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $23.89M 10-K · filed 2023-02-28 |
| 2021-09-30 | $24.62M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $26.21M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $28.52M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $25.69M 10-K · filed 2022-03-01 |
| 2020-09-30 | $30.01M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $24.85M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $22.13M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $18.61M 10-K · filed 2021-02-25 |
| 2019-09-30 | $21.37M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $18.51M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $23.74M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $20.73M 10-K · filed 2020-02-27 |
| 2018-09-30 | $14.95M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $12.82M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $13.02M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $8.46M 10-K · filed 2019-02-27 |
| 2017-09-30 | $14.56M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $8.04M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $6.87M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $7.55M 10-K · filed 2018-02-27 |
| 2014-03-31 | $1.89M 10-Q · filed 2014-05-06 |
| 2013-12-31 | $1.82M 10-Q · filed 2014-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |